Why Are These ASX Healthcare Stocks Down Today?

Sonal Goyal

27 October 2026 04:27 PM AEDT

Why Are These ASX Healthcare Stocks Down Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Lumos Diagnostics (ASX:LDX) traded at $0.067, down 20.24%. FebriDx is being ordered at 265 US sites across 29 states as of 11 October 2026.
Botanix Pharmaceuticals (ASX:BOT) traded at $0.012, down 11.54%. Total Sofdra prescriptions shipped rose 5.3% to 35,130 in Q1 FY27.
Invex Therapeutics (ASX:IXC) traded at $0.10, down 16.67%. Invex agreed to acquire 100% of Rekover Therapeutics for 45,000,000 shares and 91,250,000 performance rights.

Shares in Lumos Diagnostics Holdings Ltd (ASX:LDX), Botanix Pharmaceuticals Ltd (ASX:BOT) and Invex Therapeutics Ltd (ASX:IXC) were trading lower during the 27 October 2026 trading session: Lumos Diagnostics at $0.067, down 20.24%; Botanix Pharmaceuticals at $0.012, down 11.54%; Invex Therapeutics at $0.10, down 16.67%. At the same time, the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Three healthcare companies with diagnostics, dermatology and Drug Development businesses traded lower.

Lumos Diagnostics Holdings Ltd (ASX:LDX)

Lumos Diagnostics shares traded at $0.067, down 20.24%, during the session. Lumos reported 265 US sites ordering FebriDx, Q1 FY27 Revenue of US$2.0 million and cash of US$11.8 million, while its paediatric study enrolled below plan. The announcement is dated 27 October 2026.

Botanix Pharmaceuticals Ltd (ASX:BOT)

Botanix Pharmaceuticals shares traded at $0.012, down 11.54%, during the session. Botanix reported Sofdra prescriptions up 5.3%, flat net revenue of $10.1 million, cash of $24.4 million and new cost actions in its Q1 FY27 report. The announcement is dated 27 October 2026.

Invex Therapeutics Ltd (ASX:IXC)

Invex Therapeutics shares traded at $0.10, down 16.67%, during the session. Invex agreed to acquire Rekover Therapeutics for shares and performance rights, alongside placements totalling $10 million at $0.08 per share, subject to Shareholder approval.

Sector Context

The broader market was higher during the session, with the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Biotechnology and specialty pharmaceutical companies report progress through regulatory meetings, clinical studies, licensing and Capital raisings.

Risks

Items noted in the companies’ materials include the paediatric study is enrolling below plan, and the study parameters may require FDA discussion; Net revenue was flat despite higher gross sales, and cash fell by $12.2 million over the quarter; the Acquisition and the larger Placement depend on shareholder approval and an independent expert’s report.

What Lies Ahead

The documents point to the following next steps: for Lumos Diagnostics, The update points to additional emergency department sites in Q2 FY27, discussions with BARDA and the FDA, continued site evaluations and the respiratory season ordering pattern; for Botanix Pharmaceuticals, improvement in gross-to-net Yield in Q2 FY27 if other factors hold, and to the cost actions and strategic opportunities noted; for Invex Therapeutics, the general meeting expected in late November or early December 2026, completion of the acquisition and the start of the REVIVE study.

Closing View

LDX, BOT and IXC fell during the session. Two of the three released updates on 27 October 2026 or 26 October 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.